GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

Clinical trial NCT05189210 · COMPLETED

Trial details

NCT number: NCT05189210
Sponsor: GemVax & Kael
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Mild to Moderate Alzheimer's Disease

Start date: 2022-10-05
Primary completion: 2025-04-03
Enrollment: 199

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.